PTC THERAPEUTICS, INC.PTCTEarnings & Financial Report

Nasdaq · pharmaceutical industry

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Revenue

$211.0M

Gross Profit

N/A

Operating Profit

$3.0M

Net Profit

$15.9M

Gross Margin

N/A

Operating Margin

1.4%

Net Margin

7.5%

YoY Growth

7.2%

EPS

$0.20

Financial Flow

PTC THERAPEUTICS, INC. Q3 2025 Financial Summary

PTC THERAPEUTICS, INC. reported revenue of $211.0M for Q3 2025, with a net profit of $15.9M (7.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$211.0M
Net Profit	$15.9M
Gross Margin	N/A
Operating Margin	1.4%
Report Period	Q3 2025

PTC THERAPEUTICS, INC. Annual Revenue by Year

PTC THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $806.8M).

Year	Annual Revenue
2024	$806.8M
2023	$937.8M
2022	$698.8M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$307.1M	$210.1M	$186.7M	$196.8M	$213.2M	$1.18B	$178.9M	$211.0M
YoY Growth	83.4%	-4.7%	-12.7%	0.1%	-30.6%	459.7%	-4.2%	7.2%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$1.90B	$1.79B	$1.92B	$1.84B	$1.71B	$2.66B	$2.63B	$2.64B
Liabilities	$2.71B	$2.68B	$2.90B	$2.90B	$2.80B	$2.84B	$2.84B	$2.80B
Equity	$-818.6M	$-893.9M	$-980.2M	$-1.05B	$-1.10B	$-185.8M	$-206.5M	$-155.8M